Strategies for AE Management with T-DXd in Breast Cancer

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.

A study of patients who received the KEYNOTE-522 regimen showed an improved pathologic complete response in real-world data vs what study data showed.